AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7877584 — intervention group
Group type: EXPERIMENTAL
Intervention: SST+MLD (standard surgical treatment plus medicinal lymph node dissection)
Number of subjects: 172
Study 7877584 — intervention group
Group type: COMPARATOR
Intervention: SST only (standard surgical treatment)
Number of subjects: 172
Study 7877584 — intervention group
Group type: EXPERIMENTAL
Intervention: SST+MLD
Number of subjects: 172
Study 2899718 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 45
Study 2899718 — intervention group
Group type: COMPARATOR
Intervention: Urokinase
Number of subjects: 45
Study 31684757 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time usage (various types)
Number of subjects: 0
Study 30272428 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term rent subsidies
Number of subjects: 2282
Study 30272428 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term rent subsidies
Number of subjects: 2282
Study 30272428 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional housing with intensive psychosocial services
Number of subjects: 2282
Study 30272428 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2282
Study 27864462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IAT)
Number of subjects: 449
Study 27864462 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 449
Study 27864462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IAT) for grade 3 collateral status
Number of subjects: 449
Study 27864462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IAT) for grade 2 collateral status
Number of subjects: 449
Study 27864462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IAT) for grade 1 collateral status
Number of subjects: 449
Study 27864462 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control) for grade 0 collateral status
Number of subjects: 449
Study 26334726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose intravenous combination of 3 mg/mL ibuprofen and 10 mg/mL paracetamol
Number of subjects: 30
Study 26334726 — intervention group
Group type: COMPARATOR
Intervention: Oral formulation of the same doses of ibuprofen and paracetamol
Number of subjects: 30
Study 24014734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (1000 IU/day)
Number of subjects: 2259
Study 21740249 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 491
Study 21740249 — intervention group
Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 491
Study 19861516 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 2166
Study 19861516 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 2166
Study 16611155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological agents to prevent aneurysm expansion and rupture
Number of subjects: 0
Study 16611155 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 15475664 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy
Number of subjects: 145
Study 15475664 — intervention group
Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy
Number of subjects: 145
Study 15475664 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 145
Study 11733267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 30
Study 11733267 — intervention group
Group type: COMPARATOR
Intervention: Posterior episcleral buckle procedure (PEBP)
Number of subjects: 30
Study 9812477 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella typhi Vi capsular polysaccharide vaccine (Vi)
Number of subjects: 777
Study 9812477 — intervention group
Group type: COMPARATOR
Intervention: Diluted solution (DS) of Vi (placebo)
Number of subjects: 777
Study 7898090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 4 mg
Number of subjects: 0
Study 7898090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (1.25, 3.75, 10, and 30 mg)
Number of subjects: 0
Study 7898090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril and Propranolol
Number of subjects: 0
Study 7898090 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 2606883 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 15
Study 2606883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31773444 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in days of unhealthy drinking
Number of subjects: 566
Study 31773444 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in days of unhealthy drinking
Number of subjects: 566
Study 31241192 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application-assisted nurse-led management model
Number of subjects: 152
Study 31241192 — intervention group
Group type: COMPARATOR
Intervention: Nurse-led asthma management and routine treatment measures (including inhaled corticosteroids)
Number of subjects: 152
Study 28346869 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex tone with an 8% mistuned harmonic paired with visual displays of one or two bouncing balls
Number of subjects: 0
Study 28346869 — intervention group
Group type: COMPARATOR
Intervention: In-tune complex tone paired with visual displays
Number of subjects: 0
Study 28346869 — intervention group
Group type: COMPARATOR
Intervention: Mistuned harmonic complex paired with visual displays
Number of subjects: 0
Study 24733191 — intervention group
Group type: COMPARATOR
Intervention: MTX 12.5 mg once a week
Number of subjects: 207
Study 24733191 — intervention group
Group type: EXPERIMENTAL
Intervention: TwHF 20 mg three times a day
Number of subjects: 207
Study 24733191 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX+TwHF combination
Number of subjects: 207
Study 24733191 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 207
Study 24733191 — intervention group
Group type: EXPERIMENTAL
Intervention: TwHF
Number of subjects: 207
Study 24733191 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 207
Study 23141837 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 800μg/day
Number of subjects: 84
Study 23141837 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600μg/day
Number of subjects: 84
Study 23141837 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400μg/day plus montelukast 10μg/day
Number of subjects: 84
Study 23141837 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400μg/day plus carbamylated allergoid of betulaceae
Number of subjects: 84
Study 23141837 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400μg/day plus immunotherapy
Number of subjects: 84
Study 23141837 — intervention group
Group type: COMPARATOR
Intervention: Control group (Budesonide 800μg/day)
Number of subjects: 84
Study 23141837 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups except budesonide 800μg/day
Number of subjects: 84
Study 21705894 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily evaluation and spontaneous breathing test with 10 cm H2O pressure support and 5 cm H2O positive end-expiratory pressure for 2 hours
Number of subjects: 294
Study 21705894 — intervention group
Group type: COMPARATOR
Intervention: Standard care procedures for weaning
Number of subjects: 294
Study 18206846 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed sequence of action effects with randomly varying transformation rules
Number of subjects: 0
Study 18206846 — intervention group
Group type: COMPARATOR
Intervention: Fixed sequence of transformation rules with randomly varying action effects
Number of subjects: 0
Study 16393445 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once daily
Number of subjects: 808
Study 16393445 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 808
Study 16393445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study 14744173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 107
Study 14744173 — intervention group
Group type: COMPARATOR
Intervention: Nondirective Supportive Therapy (NST)
Number of subjects: 107
Study 14744173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime history of sexual abuse
Number of subjects: 107
Study 10993619 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt cessation of TPN
Number of subjects: 21
Study 10993619 — intervention group
Group type: COMPARATOR
Intervention: Tapered protocol of TPN
Number of subjects: 21
Study 9132506 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous opioid blockade with naltrexone
Number of subjects: 58
Study 9132506 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 58
Study 1621026 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden 4 mg
Number of subjects: 16
Study 1621026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1621026 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Biperiden and Placebo)
Number of subjects: 16
Study 6359996 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of Aspergillus fumigatus carbohydrate by radioimmunoassay
Number of subjects: 39
Study 6359996 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody detection by enzyme‐linked immunosorbent assay
Number of subjects: 39
Study 6359996 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic microbiologic and histopathologic procedures
Number of subjects: 39
Study 6359996 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective nasal cultures
Number of subjects: 39
Study 6359996 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunoassay for A. fumigatus antigen
Number of subjects: 39
Study 6359996 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigenemia detection in second trial
Number of subjects: 39
Study 30624600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition (Lipid-based nutrient supplements and infant and young child feeding counseling)
Number of subjects: 2169
Study 30624600 — intervention group
Group type: EXPERIMENTAL
Intervention: Water, sanitation, and handwashing (WSH)
Number of subjects: 2169
Study 30624600 — intervention group
Group type: COMPARATOR
Intervention: WSH+N
Number of subjects: 2169
Study 30624600 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2169
Study 30046691 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab (1, 2, 4, or 8 g)
Number of subjects: 80
Study 30046691 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab (1, 2, 4, or 5 g) with dabigatran (220 mg bid)
Number of subjects: 80
Study 30046691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30046691 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 80
Study 25895688 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopic technique (MLC)
Number of subjects: 40
Study 25895688 — intervention group
Group type: COMPARATOR
Intervention: Standard multiport access (CLMP)
Number of subjects: 40
Study 24374517 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 4705
Study 24374517 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 4705
Study 22813840 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine plus aripiprazole
Number of subjects: 24
Study 22813840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus aripiprazole
Number of subjects: 24
Study 19318984 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (in amlodipine-based therapy)
Number of subjects: 10305
Study 19318984 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (in atenolol-based therapy)
Number of subjects: 10305
Study 17728418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychosocial intervention (30 sessions over 9 months of interpersonal and social rhythm therapy, cognitive behavior therapy [CBT], or family‐focused therapy)
Number of subjects: 152
Study 17728418 — intervention group
Group type: COMPARATOR
Intervention: Collaborative care (a 3‐session psychoeducational treatment)
Number of subjects: 152
Study 15637976 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated power toothbrush/toothpaste dispensing system (IntelliClean System from Sonicare and Crest)
Number of subjects: 66
Study 15637976 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrushing coupled with daily flossing (positive control)
Number of subjects: 66
Study 11431729 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg bolus plus 0.05 mg/kg.min for 120 minutes)
Number of subjects: 7
Study 11431729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (the vehicle)
Number of subjects: 7
Study 9736100 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative and medically oriented day hospital care
Number of subjects: 177
Study 9736100 — intervention group
Group type: COMPARATOR
Intervention: Control group (home care treatment)
Number of subjects: 177
Study 8303937 — intervention group
Group type: EXPERIMENTAL
Intervention: LPF toxoid (25 micrograms)
Number of subjects: 75
Study 8303937 — intervention group
Group type: EXPERIMENTAL
Intervention: LPF/FHA (25 micrograms each)
Number of subjects: 75
Study 8303937 — intervention group
Group type: COMPARATOR
Intervention: DTP whole‐cell pertussis vaccine
Number of subjects: 75
Study 2659874 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg finoptin
Number of subjects: 44
Study 2659874 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg fosfobion
Number of subjects: 44
Study 30499926 — intervention group
Group type: EXPERIMENTAL
Intervention: Express
Number of subjects: 113
Study 30499926 — intervention group
Group type: COMPARATOR
Intervention: I‐InTERACT
Number of subjects: 113
Study 30499926 — intervention group
Group type: COMPARATOR
Intervention: IRC
Number of subjects: 113
Study 28482839 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkanna tinctoria extract ointment (20%)
Number of subjects: 0
Study 28482839 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing (control)
Number of subjects: 0
Study 25608876 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Care Model
Number of subjects: 35
Study 22837547 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention delivered by dental hygienists; duration: 3-5 minutes; includes motivational interviewing and personalized normative feedback.
Number of subjects: 0
Study 21770995 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-abrasive device (AAD) with amino acid glycine powder
Number of subjects: 30
Study 21770995 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement (MDA) using carbon curets and antiseptic therapy with chlorhexidine digluconate
Number of subjects: 30
Study 19309347 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl aminolevulinate (MAL) photodynamic therapy (PDT)
Number of subjects: 131
Study 19309347 — intervention group
Group type: COMPARATOR
Intervention: Placebo PDT
Number of subjects: 131
Study 16679086 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DESs)
Number of subjects: 741
Study 16679086 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 741
Study 12580662 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term isokinetic training (2 days of velocity-specific training)
Number of subjects: 3
Study 12580662 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 3
Study 10736979 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80
Study 10736979 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study 10736979 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 9366665 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide hydrochloride
Number of subjects: 40
Study 9366665 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 40
Study 9366665 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide hydrochloride and 0.5% timolol maleate together
Number of subjects: 40
Study 1561524 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg every morning for 10 days)
Number of subjects: 10
Study 1561524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4015380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiation and fluorouracil as adjuvant therapy
Number of subjects: 43
Study 4015380 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 43
Study 29121431 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate (CP) in aqueous solution (AS)
Number of subjects: 102
Study 29121431 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% triamcinolone acetonide (TA) in aqueous solution (AS)
Number of subjects: 102
Study 29121431 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate (CP) in orabase (OB)
Number of subjects: 102
Study 29121431 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% triamcinolone acetonide (TA) in orabase (OB)
Number of subjects: 102
Study 29121431 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with continuous symptoms
Number of subjects: 102
Study 29121431 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with intermittent symptoms
Number of subjects: 102
Study 29121431 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects observed in patients
Number of subjects: 102
Study 29121431 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment for >6 months
Number of subjects: 102
Study 27615399 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual trans-vaginal ultrasound (TVU) for 4 years and CA-125 testing for 6 years with a cutoff at 35 U/mL
Number of subjects: 39105
Study 27615399 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 39105
Study 24219852 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Fr NBD catheter
Number of subjects: 165
Study 24219852 — intervention group
Group type: COMPARATOR
Intervention: 6 Fr NBD catheter
Number of subjects: 165
Study 22519736 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 36
Study 22519736 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 36
Study 22519736 — intervention group
Group type: COMPARATOR
Intervention: Mix50
Number of subjects: 36
Study 20447617 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) 20 IU
Number of subjects: 48
Study 20447617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19083452 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-g dose of strong-gelling alginate
Number of subjects: 0
Study 19083452 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 0
Study 16636410 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Impedance Tomography (f‐EIT) based on back projection
Number of subjects: 4
Study 16636410 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous Iterative Reconstruction Technique (SIRT)
Number of subjects: 4
Study 16636410 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomograms
Number of subjects: 4
Study 16636410 — intervention group
Group type: COMPARATOR
Intervention: Regional resistivity data
Number of subjects: 4
Study 12941422 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies used to deplete lymphocytes or block T-cell function
Number of subjects: 0
Study 12941422 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional immunosuppressive agents
Number of subjects: 0
Study 10202052 — intervention group
Group type: EXPERIMENTAL
Intervention: Variceal ligation
Number of subjects: 88
Study 10202052 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy
Number of subjects: 88
Study 7595729 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PC) with cyclophosphamide 600 mg/m2, epidoxorubicin 60 mg/m2, and fluorouracil 600 mg/m2 (CEF)
Number of subjects: 600
Study 7595729 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PC)
Number of subjects: 600
Study 2151889 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (0.5 mg/kg)
Number of subjects: 30
Study 2151889 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (0.5 mg/kg) + epinephrine (0.1 micrograms/kg/min)
Number of subjects: 30
Study 2151889 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (0.1 micrograms/kg/min)
Number of subjects: 30
Study 161652 — intervention group
Group type: EXPERIMENTAL
Intervention: Björk-Shiley (B-S) valves
Number of subjects: 78
Study 161652 — intervention group
Group type: COMPARATOR
Intervention: Lillehei-Kaster (L-K) valves
Number of subjects: 78
Study 30251569 — intervention group
Group type: EXPERIMENTAL
Intervention: Group prenatal care (GPC)
Number of subjects: 84
Study 30251569 — intervention group
Group type: COMPARATOR
Intervention: Individual prenatal care (IPC)
Number of subjects: 84
Study 31577705 — intervention group
Group type: EXPERIMENTAL
Intervention: Early preoperative analgesia (EPA)
Number of subjects: 296
Study 31577705 — intervention group
Group type: COMPARATOR
Intervention: Postoperative analgesia (POA)
Number of subjects: 296
Study 28370357 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived MSCs infused weekly for 4 weeks (1.0 to 10 × 10^5 cells/kg)
Number of subjects: 110
Study 28370357 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 110
Study 28370357 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived MSCs
Number of subjects: 110
Study 26215351 — intervention group
Group type: EXPERIMENTAL
Intervention: Teething rings
Number of subjects: 270
Study 26215351 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuddle therapy
Number of subjects: 270
Study 26215351 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubbing the gums
Number of subjects: 270
Study 26215351 — intervention group
Group type: COMPARATOR
Intervention: Ice
Number of subjects: 270